Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016430 · ClinicalTrials.gov registry record · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
A NA study of Cardiovascular Risk Factor and Dietary Modification, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT02016430: Recruiting NA study of Cardiovascular Risk Factor and Dietary Modification, sponsored by The Cleveland Clinic.
NCT02016430 is a NA study of Cardiovascular Risk Factor and Dietary Modification that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 170 participants, below the 3,063-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02016430, a NA study of Cardiovascular Risk Factor and Dietary Modification, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.
Primary Outcome
The change in TMAO concentration measured in blood samples
Conditions Studied
Interventions
- BEHAVIORAL MeLT Dietary intervention
- BEHAVIORAL TLC Dietary intervention
- BEHAVIORAL MeLT dietary intervention with TMAO
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2014-04-04 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT02016430 shows while recruiting
NCT02016430 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 3,063-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 3 interventions - of which MeLT Dietary intervention is the first listed.
NCT02016430 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02016430 about?
NCT02016430 is a clinical study titled "Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)". Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.
What is the current status of trial NCT02016430?
This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2014-04-04. Estimated completion is 2026-12.
What conditions does trial NCT02016430 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor, Dietary Modification.
What interventions are being tested in trial NCT02016430?
The interventions under investigation include: MeLT Dietary intervention (BEHAVIORAL), TLC Dietary intervention (BEHAVIORAL), MeLT dietary intervention with TMAO (BEHAVIORAL).
Who is sponsoring clinical trial NCT02016430?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02016430 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02016430's enrollment target sits among peer trials
170 9th of 31 higher than 23 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
-
Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans
RECRUITING · NA
-
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
ACTIVE NOT RECRUITING · NA
-
Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
- NCT04614103 · 170 participants · Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI